AstraZeneca Says Its COVID-19 Vaccine is 79% Effective
Summary from the AllSides News Team
Featured Coverage of this Story
From the Left
AstraZeneca’s U.S. trial shows coronavirus vaccine is 79 percent effectiveOxford University and AstraZeneca reported on Monday that their coronavirus "vaccine for the world" was safe and 79 percent effective overall, according to data from a long-awaited clinical trial in the United States, alongside other studies in Chile and Peru. The two-shot regimen was completely effective at preventing severe cases of illness.
In a news release, the Oxford researchers, who developed the easily transported $4 shot for the British-Swedish pharmaceutical giant AstraZeneca, said their coronavirus vaccine is “safe and highly effective, adding to previous trial data from the United Kingdom,...
From the Left
AstraZeneca: US data shows vaccine effective for all adultsAstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease, including in older adults, in final-stage U.S. testing, the company announced Monday.
AstraZeneca said its experts did not identify any safety concerns related to the vaccine, including finding no increased risk of rare blood clots identified in Europe. The question now is whether the findings will help rebuild public confidence in the vaccine around the world, as the company seeks to win clearance in the United States
In a statement, AstraZeneca said its COVID-19...
From the Right
AstraZeneca COVID-19 vaccine 100% effective at preventing hospitalizations, company saysNew data from AstraZeneca’s coronavirus vaccine trial, which has yet to receive emergency authorization in the United States, is showing positive results.
The latest data from the company published on Monday showed that the vaccine has an efficacy of 79% at preventing symptomatic cases of the coronavirus while being 100% effective at stopping severe disease and hospitalization. The trial included 32,449 participants, and a fifth of them, approximately 8,000 people, were 65 years old or older. 60% of study participants have comorbidities that make them more at risk for a...
AllSides Picks
May 11th, 2024
May 10th, 2024
May 9th, 2024